One-Year Phase 3 Data Show 60% PASI 100 and No New Safety Signals
One-year Phase 3 data from ICONIC-ADVANCE 1 & 2 and ICONIC-LEAD show PASI 100 rates rising from Week 24 to 52 with no new safety signals for ICOTYDE, an IL-23 receptor peptide for plaque psoriasis. Sixty percent of adolescents achieved complete skin clearance and 86% reached PASI 90 at one year.
1. Presentation at AAD Annual Meeting
Protagonist presented one-year Phase 3 results for ICOTYDE at the 2026 American Academy of Dermatology Annual Meeting, highlighting the drug’s IL-23 receptor mechanism and once-daily oral dosing for moderate-to-severe plaque psoriasis.
2. ICONIC-ADVANCE 1 & 2 Results
In the ICONIC-ADVANCE 1 and 2 trials, PASI 100 rates increased from Week 24 through Week 52 with no new safety signals; patients switching from placebo to ICOTYDE at Week 16 achieved comparable skin clearance by Week 52.
3. ICONIC-LEAD Adolescent Outcomes
The ICONIC-LEAD study in adolescents showed 60% achieved complete skin clearance (PASI 100) and 86% reached PASI 90 at one year, with 92% maintaining that response from Week 24 to Week 52 and no new adverse events identified.
4. Commercial and Financial Terms
Under the 2017 collaboration, Johnson & Johnson will commercialize ICOTYDE while Protagonist retains development rights and is eligible for a $50 million approval milestone plus 6–10% tiered royalties and up to $580 million in additional milestones.